We, therefore, speculated that the suspected metabolic induction of a HR-ness phenotype should sensitize cancer cells to combined treatment with inhibitors of complementary end joining dependent DNA repair pathways, e.g., the PARP1-dependent alternative end joining (alt-EJ), or the DNA-PKcs-dependent NHEJ. Here, PRKDC is linked to cancer.